NEW YORK – With the success of drugs like Merck's pembrolizumab (Keytruda) and Loxo Oncology and Bayer's larotrectinib (Vitrakvi), many companies that make oncology therapies are now trying their hand at developing histology-agnostic cancer drugs. But getting these treatments into patients' hands isn't simple — they must be tested in specifically designed clinical trials, approved by regulators, and paid for by insurance companies.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.